

11-28-2012

# Adrenoceptor function and expression in bladder urothelium and lamina propria

Christian Moro

*Bond University*, [Christian\\_Moro@bond.edu.au](mailto:Christian_Moro@bond.edu.au)

Lotti Tajouri

*Bond University*, [lotti\\_tajouri@bond.edu.au](mailto:lotti_tajouri@bond.edu.au)

Russ Chess-Williams

*Bond University*, [Russ\\_Chess-Williams@bond.edu.au](mailto:Russ_Chess-Williams@bond.edu.au)

Follow this and additional works at: [http://epublications.bond.edu.au/hsm\\_pubs](http://epublications.bond.edu.au/hsm_pubs)



Part of the [Urology Commons](#)

---

## Recommended Citation

Christian Moro, Lotti Tajouri, and Russ Chess-Williams. (2012) "Adrenoceptor function and expression in bladder urothelium and lamina propria" *Urology*, Online, i.e1-i.e7: ISSN 0090-4295.

[http://epublications.bond.edu.au/hsm\\_pubs/452](http://epublications.bond.edu.au/hsm_pubs/452)

## **Adrenoceptor function and expression in the bladder urothelium and lamina propria**

Christian Moro BSc<sup>a</sup>

Lotti Tajouri PhD<sup>a</sup>

Russ Chess-Williams PhD<sup>a\*</sup>

\* Corresponding author: Professor R. Chess-Williams, <sup>a</sup>Bond Urology Group, Faculty of Health Sciences and Medicine, Bond University, Gold Coast, Queensland, 4229, Australia.

Tel: +61 (0)7 55954420

Fax: +61 (0)7 55954538

Email: [rchesswi@bond.edu.au](mailto:rchesswi@bond.edu.au)

### **Conflicts of interest**

The authors declare that there are no conflicts of interest

**Section:** Basic and Translational Science

**Runninghead:** Adrenoceptors in the urothelium/lamina propria.

**Word count of manuscript text:** 2979

**Word count of abstract:** 237

**References:** 29

**Number of Figures/Tables:** 4

*Keywords:* Urinary bladder, urothelium, myofibroblasts, bladder mucosa, adrenoceptors, lamina propria.

## **Acknowledgements**

C. Moro was in receipt of an Australian Postgraduate Award and a QLD Smart Futures PhD Scholarship Program. The authors would like to thank Astellas Pharma for the gift of tamsulosin. The porcine-specific primers were designed by Kevin Ashton (Bond University, Australia).

## **Statement of conflicts of Interest:**

The authors state no conflict of interest.

## **Introduction**

The functions of the bladder include both relaxation, which occurs during bladder filling, and contraction which occurs during the emptying phase of the micturition cycle. Detrusor smooth muscle contraction to muscarinic agonists is mediated via M<sub>3</sub> muscarinic receptors,<sup>1</sup> while noradrenaline relaxes the tissue via  $\beta$ -adrenoceptors, although the subtype involved appears to be species dependent (reviewed by Michel et al., 2006).  $\alpha$ -adrenoceptors are also present on the detrusor muscle, but receptor density is low and responses to  $\alpha$ -adrenoceptor agonists are small or non-existent.<sup>2</sup>

Over recent years the importance of the inner epithelial lining of the bladder, the urothelium, and the underlying lamina propria in regulating bladder function has been increasingly recognised. The lamina propria, is the layer of tissue between the inner epithelial layer of the bladder wall and the underlying detrusor smooth muscle. This inner region of the bladder wall has a barrier function, but also when stretched it releases a number of factors that influence detrusor contraction and afferent nerve sensitivity.<sup>3</sup> In addition, the urothelium with lamina propria from the dome of the pig bladder<sup>4,5</sup> and also strips of lamina propria from

the rabbit urethra<sup>6,7</sup> have been shown to contract to agonists such as carbachol, neurokinin A and noradrenaline. Isolated strips of urothelium with lamina propria also develop spontaneous contractile activity, with carbachol and also stretch-induced release of acetylcholine mediating increases in spontaneous contractile frequency via M<sub>3</sub> receptors.<sup>8</sup>

The lamina propria of the human bladder has been shown to be immunoreactive for tyrosine hydroxylase<sup>9,10</sup>, indicating a sympathetic innervations, and the lamina propria of the rabbit urethra contracts in response to phenylephrine demonstrating that  $\alpha_1$ -adrenoceptors are present.<sup>6</sup> Three  $\alpha_1$ -adrenoceptor subtypes have been identified at the molecular and functional level ( $\alpha_{1A}, \alpha_{1B}, \alpha_{1D}$ ,<sup>11</sup>) and another, termed the  $\alpha_{1L}$ -adrenoceptor that is a pharmacological phenotype which arises from the  $\alpha_{1A}$ -adrenoceptor gene and has a low affinity for prazosin, has been recognised in functional experiments.<sup>12</sup> Which  $\alpha_1$ -adrenoceptor subtypes are present in porcine urothelium and lamina propria and their functional role has not been investigated. Similarly, all three  $\beta$ -adrenoceptor subtypes are expressed in the human lamina propria at the mRNA and protein level,<sup>13</sup> but their influence on contractile activity is unknown. Many studies have identified the pig bladder as a suitable model for the human bladder it and demonstrates similarities in the expression of adrenoceptors.<sup>14-16</sup> The present study examines which  $\alpha$ - and  $\beta$ -adrenoceptors are expressed in the pig urinary bladder urothelium and lamina propria, and identifies the adrenoceptor subtypes responsible for mediating the spontaneous frequency and tension responses of this tissue.

## Material and methods

### *Functional organ bath studies*

Fresh bladders from Large White-Landrace pigs (6 months old, ~80 kg) were obtained from a local abattoir and immediately immersed in cold Krebs-bicarbonate solution (composition in mM: NaCl 188.4, NaHCO<sub>3</sub> 24.9, CaCl<sub>2</sub> 1.9, MgSO<sub>4</sub> 1.15, KCL 4.7, KH<sub>2</sub>PO<sub>4</sub> 1.15 and D-glucose 11.7). The bladders were opened longitudinally and full thickness strips of anterior wall from the dome region were removed. From these tissues, strips of urothelium with lamina propria were prepared (20 x 5 mm) and immersed in Krebs-bicarbonate solution, maintained at 37°C and gassed with 5% CO<sub>2</sub> in oxygen. The tissues were attached to isometric force transducers (ADInstruments MCT050/D) and tensions recorded with a Powerlab system using Labchart v7 software (ADInstruments, Castle Hill, Australia). After washing with fresh Krebs solution the tissues were allowed to equilibrate for 45 minutes under a baseline tension of ~2g before starting drug additions. For studies with antagonists, adjacent pieces of tissue were dissected, set up in pairs under identical conditions and allowed to equilibrate. One tissue was incubated with the antagonist for 30 minutes, and the other remained as a control in the absence of any antagonist. Where antagonists selective for a particular receptor subtype have been used, affinity values were obtained from the literature and the concentration carefully selected to give a maximum antagonism of the receptor without an action on the other receptor subtypes.

### *RT-PCR studies*

Strips of urothelium with lamina propria (n=6) were finely dissected with scissors under magnification and immediately immersed in RNALater solution (Ambion Inc.). The urothelium and lamina propria (~0.2 g each) was then homogenised and RNA extracted with

a Trizol *plus* RNA purification kit (Invitrogen Cat No. 12183-555) as per manufacturer's instructions. All storage of RNA was maintained at -80°C and experiments performed within 3 months of the initial extraction. A NanoDrop 1000 Spectrophotometer (Thermo Scientific) was used to measure the total RNA quantity (ng/μL) and to assess the purity (260/280 ratio). The integrity of the RNA was also performed for all extractions with formaldehyde agarose gel electrophoresis in ethidium bromide staining for 28s and 18s RNA band visualisation. cDNA synthesis was then performed using SuperScript III First-Strand Synthesis SuperMix from the qRT-PCR kit (Invitrogen). Initial incubation was in a reaction mix (10μL of 2X RT reaction mix; 2μL of reverse transcriptase enzyme mix; 8μL of eluted RNA) and performed at 25°C for 10 minutes.

An iQTM SYBR Green Super Mix (BioRad) was used to amplify the cDNA targeted genes. Real-time PCR was performed with a Research Rotor-Gene 3000 (Corbett). 5μL of cDNA was used to amplify the genes. PCR for ADRB3 was undertaken in triplicate with the following conditions: 94°C: 10min(x1), Cycle 2, 94°C:30s, 51°C:15s, 72°C:15s(x40). All other genes were investigated with the following conditions: cycle 1, 94°C 10 min(x1), Cycle 2, 94°C:30s, 60°C:30s, 72°C:30s(x45). A post-PCR amplification protocol was preset before the run to obtain melt curve representations, ramping from 50-99°C with 1°C increases every 5s. Two reference genes were examined for internal controls in realtime PCR including 18s-RNA and β-actin. 18s expression was found slightly less optimal as an internal control than β-actin. The actin gene exhibited optimal and identical expression levels across all porcine tissues. Therefore, the expression levels of each target gene were expressed relative to the PCR amplification of β-actin.

### *Data analysis and statistical procedures*

Measurements of frequency and baseline tension were taken at the peak response after the addition of each agonist. The frequency of contractions was expressed as the number of phasic waves per minute (cycles min<sup>-1</sup>) and the baseline tension as grams (g). The baseline tension was taken as the lowest point of the spontaneous phasic contractions. Mean  $\pm$  standard error of mean (SEM) values in the absence and presence of drugs were compared using a Student's two-tailed *t*-test with  $P < 0.05$  being taken as statistically significant. Prism software (GraphPad v4, San Diego, CA, USA) was used for statistical analysis of data. A one-way analysis of variance (ANOVA) with a Dunnett post test was applied for analysis of more than one sample (Table 1 only). *n* represents the number of different porcine tissues used in the study. Real-time PCR data were calculated using the cycle threshold determination method (Corbett rotor gene 6000 series software v1.7).

### *Drugs, chemical reagents and other materials*

( $\pm$ )-Noradrenaline hydrogen tartrate, CGP20712A methanesulfonate, clonidine hydrochloride, isoprenaline hydrochloride, phentolamine hydrochloride, (R)-(-)-phenylephrine hydrochloride, and prazosin hydrochloride were purchased from Sigma (St Louis, Missouri, USA). Tamsulosin was a gift provided by Astellas Pharma (Leiderdorp, NL). A61603 hydrobromide, BMY7378 dihydrochloride, BRL37344 sodium salt, CL316243 disodium salt, ICI118551 hydrochloride, ( $\pm$ )-propranolol hydrochloride, RS17053 hydrochloride, RS100329 hydrochloride, SR59230A, salbutamol sulphate, and UK14,304 were purchased from Tocris (Ellisville, Missouri, USA). Oligonucleotide primers were obtained from Geneworks (Thebarton, South Australia).

## Results

### *Spontaneous phasic contractions*

The urothelium and lamina propria exhibited spontaneous contractions within 10 minutes of being placed in the organ bath (Fig. 1). This regular phasic activity of the urothelium was present throughout the course of the experiment and occurred at a spontaneous contractile frequency of  $3.48 \pm 0.07$  cycles  $\text{min}^{-1}$  and an amplitude of  $0.68 \pm 0.03$ g (n=211).

### *Responses to noradrenaline*

Noradrenaline (10 $\mu$ M, n=8) significantly reduced the frequency of spontaneous contractions by  $15.2 \pm 6.5\%$  and baseline tension by  $22 \pm 4\%$  (Table 1). The frequency responses were significantly enhanced in the presence of phentolamine (10 $\mu$ M), noradrenaline then reducing the frequency of contractions by  $39 \pm 7\%$ , while relaxation of the tissues to noradrenaline was not significantly affected (Table 1). In contrast, in the presence of propranolol (1 $\mu$ M), responses to noradrenaline (10 $\mu$ M, n=8) were converted to increases in the rate of spontaneous contractions ( $41 \pm 7\%$  increase) and the baseline tension increased by  $52 \pm 10\%$  (Table 1).

### *$\alpha$ -adrenoceptor responses*

The  $\alpha_2$ -adrenoceptor agonists clonidine and UK14,304 are highly potent agonists at  $\alpha_2$ -adrenoceptors and produce responses at nano-molar concentrations if these receptors are present in a tissue. However at concentrations up to 1 $\mu$ M, neither agonist had any effect on either the spontaneous contractile frequency or the basal tension developed by tissues (n=8). Higher concentration of these drugs will activate  $\alpha_1$ -adrenoceptors and thus were not examined. In contrast, the  $\alpha_1$ -adrenoceptor selective agonist phenylephrine (100 $\mu$ M)

increased the spontaneous activity by  $41 \pm 8\%$  and the baseline tension by  $22 \pm 5\%$  ( $n=21$ ,  $P < 0.001$  for both). At a 10-fold lower concentration, the  $\alpha_{1A}$ -adrenoceptor selective agonist A61603 ( $10\mu\text{M}$ ) produced a similar increase in spontaneous contractile frequency  $31 \pm 4\%$  and also increased baseline tension by  $31 \pm 4\%$  ( $n=26$ ,  $P < 0.001$  for both; Fig. 1). Lower concentrations of phenylephrine ( $1\text{-}10\mu\text{M}$ ,  $n=8$ ) did not cause any significant responses for frequency or tension, yet lower concentrations of A61603 ( $3\mu\text{M}$ ,  $n=8$ ) resulted in significant increases for frequency by  $27 \pm 9\%$  ( $P < 0.05$ ) and baseline tension by  $18 \pm 5\%$  ( $P < 0.01$ ).

The increase in the frequency of contractions produced by phenylephrine was significantly reduced by low concentrations of the  $\alpha_{1A}$ -adrenoceptor antagonists, RS100329 ( $10\text{nM}$ ,  $n=8$ ) and tamsulosin ( $3\text{nM}$ ,  $n=8$ ), but not by the  $\alpha_{1D}$ -adrenoceptor selective antagonist BMY7378 ( $100\text{nM}$ ,  $n=8$ ; Fig. 2). Increases in basal tension induced by phenylephrine ( $100\mu\text{M}$ ) were similarly reduced by RS100329 ( $10\text{nM}$ ,  $n=8$ ,  $P < 0.05$ ) and tamsulosin ( $3\text{nM}$ ,  $n=8$ ,  $P < 0.05$ ), but not BMY7378 ( $100\text{nM}$ ,  $n=8$ , Fig. 2). Two antagonists that discriminate between  $\alpha_{1A}$ - and  $\alpha_{1L}$ -adrenoceptors, prazosin and RS17053 were also examined. Neither prazosin ( $10\text{nM}$ ,  $n=10$ ) nor RS17053 ( $1\mu\text{M}$ ,  $n=8$ ) had any significant effect on either frequency or tension responses to phenylephrine (Fig. 2).

### *$\beta$ -adrenoceptor responses*

Isoprenaline ( $1\mu\text{M}$ ,  $n=62$ ) reduced the spontaneous contractile frequency of tissue strips by  $34 \pm 2\%$  ( $1.21 \pm 0.08 \text{ cycles min}^{-1}$ ,  $P < 0.001$ ) and the baseline tension by  $37 \pm 2\%$  ( $0.66 \pm 0.44\text{g}$ ,  $P < 0.001$ ). A higher concentration of isoprenaline ( $10\mu\text{M}$ ,  $n=16$ ) produced a greater inhibition of the contractile frequency ( $49 \pm 1\%$ ,  $P < 0.01$ ), but the depression of baseline tension was similar to that obtained with the lower concentration of isoprenaline ( $40 \pm 3\%$ ). Salbutamol ( $1\mu\text{M}$ ,  $n=7$ ) reduced the frequency of spontaneous contractions by  $33 \pm 6\%$  and

the baseline tension by  $22 \pm 2\%$  ( $P < 0.001$  for both responses). A higher concentration of salbutamol ( $10\mu\text{M}$ ) did not induce greater inhibition of the tissues. The  $\beta_3$ -adrenoceptor selective agonist, BRL37344, at concentrations up to  $10\mu\text{M}$  ( $n=8$ ), did not affect the frequency of spontaneous contractions or baseline tension. Another  $\beta_3$ -adrenoceptor selective agonist, CL316243, was similarly without effect over a range of concentrations up to  $1\mu\text{M}$ .

Isoprenaline ( $1\mu\text{M}$ ; Fig. 2) induced relaxation and a slowing of spontaneous phasic contractions and both these responses were significantly reduced in the presence of propranolol ( $100\text{nM}$ ,  $n=8$ ) or a combination of the  $\beta_1$ -adrenoceptor antagonist CGP20712A ( $30\text{nM}$ ,  $n=8$ ) and  $\beta_2$ -adrenoceptor antagonist ICI118551 ( $70\text{nM}$ ,  $n=11$ ), but were unaffected by CGP20712A ( $\beta_1$ -adrenoceptor antagonist,  $n=8$ ), or SR59230A ( $\beta_3$ -adrenoceptor antagonist,  $n=8$ ). The  $\beta_2$ -adrenoceptor antagonist ICI118551 ( $70\text{nM}$ ,  $n=12$ ) significantly reduced frequency responses to isoprenaline ( $P < 0.05$ ), but not relaxation responses to this agonist (Fig. 2).

### *RT-PCR*

RNA was extracted from isolated urothelium and lamina propria samples ( $n=6$ , run in triplicate) and tested for integrity prior to being converted into cDNA. RNA concentrations and 260/280 ratios were as follows: Sample 1:  $602\text{ng}/\mu\text{L}$ , 2.06; Sample 2:  $699\text{ng}/\mu\text{L}$ , 2.10; Sample 3:  $1050\text{ng}/\mu\text{L}$ , 2.08; Sample 4:  $620\text{ng}/\mu\text{L}$  2.09, Sample 5:  $823\text{ng}/\mu\text{L}$ ; 2.10, Sample 6:  $590\text{ng}/\mu\text{L}$ , 2.11. The real-time PCR products for all six adrenoceptor genes and the reference gene  $\beta$ -actin were run in triplicate and the end product visualised on 2% agarose gels to identify that all genes demonstrated the correct fragment sizes. For  $\alpha_1$ -adrenoceptors, the greatest expression was observed for the  $\alpha_{1A}$ - and  $\alpha_{1B}$ -adrenoceptor subtypes, while that for the  $\alpha_{1D}$ -adrenoceptor was only half that obtained for  $\alpha_{1A}$ - and  $\alpha_{1B}$ -adrenoceptors (Fig. 3). All

three  $\beta$ -adrenoceptor subtypes were expressed in these tissues. The expression was highest for  $\beta_2$ -adrenoceptors; which was nearly double that for either  $\beta_1$ - or  $\beta_3$ -adrenoceptors (Fig. 3).

### **Comment**

In the absence of any exogenous agonist, the urothelium with lamina propria samples developed spontaneous phasic contractions. Initial data obtained with noradrenaline suggests that both  $\alpha$ - and  $\beta$ -adrenoceptors are present and functional in this tissue:  $\alpha$ -adrenoceptors mediating contraction and increases in frequency, whilst  $\beta$ -adrenoceptor activation relaxes the tissue and slows the frequency of phasic contractions. The dominant response to the physiological agonist noradrenaline is  $\beta$ -adrenoceptor mediated relaxation and slowing, since these were the responses obtained to noradrenaline in the absence of antagonists. However, these inhibitory responses to noradrenaline were enhanced in the presence of phentolamine, indicating that  $\alpha$ -adrenoceptors were reducing these inhibitory responses to noradrenaline in the absence of any antagonists. Thus both  $\alpha$ - and  $\beta$ -adrenoceptors are involved in mediating responses to the endogenous agonist noradrenaline.

#### *$\alpha$ -adrenoceptors*

The  $\alpha$ -adrenoceptor mediated responses of the urothelium and lamina propria appear to involve the  $\alpha_1$ -adrenoceptor subtype since both phenylephrine and A61603 increased phasic frequency, whilst the agonists with predominantly  $\alpha_2$ -adrenoceptor agonist selectivity, clonidine and UK14304, had no effect. The tissue expresses mRNA for all three cloned  $\alpha_1$ -adrenoceptors, but the levels of  $\alpha_{1A}$  and  $\alpha_{1B}$ -adrenoceptor mRNA are greater than that for the  $\alpha_{1D}$ -adrenoceptor subtype. On isolated tissues, both phenylephrine and the  $\alpha_{1A}$ -adrenoceptor selective agonist A61603<sup>17</sup> induced increases in baseline tension and the rate of phasic

contractions. The tension and rate responses for A61603 (10 $\mu$ M) were significantly greater than those to phenylephrine (10 $\mu$ M). Higher concentrations of phenylephrine (100 $\mu$ M) produced a greater response almost identical to that produced by the 10-fold lower concentration of A61603. These agonist data suggest that responses were mediated via the  $\alpha_{1A}$ -adrenoceptor subtype.

The antagonist data support these findings. Responses to phenylephrine were reduced by a low concentration of tamsulosin (3nM), an antagonist possessing high affinity for  $\alpha_{1A}$ - and  $\alpha_{1D}$ -adrenoceptors.<sup>18</sup> Thus responses were not mediated via  $\alpha_{1B}$ -adrenoceptors. In addition, rate and tension responses to phenylephrine were potently inhibited by RS100329, a selective antagonist for the  $\alpha_{1A}$ -adrenoceptor subtype. RS100329 has a pKi at  $\alpha_{1A}$ -adrenoceptors of 9.6 and demonstrates a 126- and 50-fold selectivity over  $\alpha_{1B}$  and  $\alpha_{1D}$ -adrenoceptor subtypes,<sup>19,20</sup> thus at the concentration used in the present study (10nM) it would only have an action at  $\alpha_{1A}$ -adrenoceptors. The lack of involvement of  $\alpha_{1D}$ -adrenoceptors was confirmed using BMY7378, an antagonist with a greater than 100-fold high affinity for the  $\alpha_{1D}$ -adrenoceptor subtype over  $\alpha_{1A}$  and  $\alpha_{1B}$ -adrenoceptors.<sup>21,22</sup> The lack of effect at a concentration of 100nM with BMY7378 supports the conclusion that  $\alpha_{1D}$ -adrenoceptors are not involved in mediating responses of the urothelium and lamina propria, and that the  $\alpha_{1A}$ -adrenoceptor is the functional  $\alpha_1$ -adrenoceptor in this tissue.

A number of studies have demonstrated that contractions of the bladder neck and prostate are mediated via  $\alpha_1$ -adrenoceptors that, unlike the cloned receptors, have a low affinity for the antagonist prazosin and this putative receptor subtype has been termed the  $\alpha_{1L}$ -adrenoceptor or  $\alpha_{1A/L}$ -adrenoceptor.<sup>11</sup> It is generally accepted that this functional receptor exists as a conformational state of the  $\alpha_{1A}$ -adrenoceptor, but the mechanisms involved are unclear and it

has been suggested that experimental conditions<sup>23,24</sup> or specific intracellular proteins<sup>25</sup> may be involved. Both prazosin and RS17053 have a low affinity for this form of the receptor compared to the  $\alpha_{1A}$ -adrenoceptor, and the lack of effect for these antagonists in the present study suggests that it is this conformational state ( $\alpha_{AL}$ -adrenoceptor) that mediates contraction of this tissue.

### *$\beta$ -adrenoceptors*

Noradrenaline, isoprenaline and salbutamol all induced relaxation of tissues and a slowing of the frequency of phasic contractions. Propranolol antagonised the inhibitory effects of isoprenaline and abolished those to noradrenaline, converting them to a small contraction and an increase in phasic rate of contractions to noradrenaline. All three subtypes of  $\beta$ -adrenoceptor ( $\beta_1$ ,  $\beta_2$  and  $\beta_3$ ) were present at the mRNA level, with the expression of  $\beta_2$ -adrenoceptors being double that of either the  $\beta_1$ - or  $\beta_3$ -adrenoceptor subtypes. Isoprenaline reduced the rate of phasic contractions and these inhibitory responses were reduced when  $\beta_2$ -adrenoceptors were antagonised with either propranolol ( $\beta_1$ - and  $\beta_2$ - antagonist), ICI118551 ( $\beta_2$ -antagonist) or a combination of ICI118551 and CGP20712A ( $\beta_1$ - antagonist). The responses were insensitive to CGP20712A alone or SR59230A ( $\beta_3$ - antagonist) indicating  $\beta_2$ -adrenoceptors are the predominant functional  $\beta$ -adrenoceptor subtype inhibiting spontaneous contractile frequency in these tissues. For relaxation responses, combined  $\beta_1$ - and  $\beta_2$ -adrenoceptor antagonism appeared to be required to significantly inhibit responses to isoprenaline and CGP20712A alone, ICI118551 alone or SR59230A alone failed to influence responses. In some species, the responses of detrusor smooth muscle to isoprenaline are mediated via  $\beta_3$ -adrenoceptors, but for porcine urothelium and lamina propria, selective concentrations of SR59230A did not affect frequency or tension responses to isoprenaline, and also CL316243 and BRL37344, two selective  $\beta_3$ -adrenoceptor agonists did not influence

either response. Thus inhibitory responses of the urothelium and lamina propria to isoprenaline appear to be mediated predominantly by  $\beta_2$ -adrenoceptors with a possible contribution from  $\beta_1$ -adrenoceptors for tension responses.

The mechanisms involved in these responses of the urothelium and lamina propria are not clear. Tension responses to neurokinin A and carbachol are present after fine dissection and removal of smooth muscle from the preparations and it has been suggested that myofibroblasts may be involved.<sup>5,8</sup> In addition, spontaneously generated electrophysiological events have been observed in myofibroblasts located within the lamina propria.<sup>26</sup> The function of this contractile activity is also uncertain. It may act to ensure folding of the urothelium in the empty bladder or alternatively it may act to enhance sensory nerve function.<sup>27</sup> It has been reported that spontaneous calcium and electrical activity arise in the urothelium-lamina propria interface and pass into the detrusor regions<sup>28</sup> and this is increased in tissues from cats with interstitial cystitis.<sup>29</sup> Therefore, in situations where electrical coupling is enhanced, it may be possible that the lamina propria may drive larger spontaneous contractions of the detrusor smooth muscle.

## **Conclusions**

In conclusion, the urothelium and lamina propria of the pig bladder develops spontaneous contractile activity that can be regulated by the sympathetic nervous system. The force of contraction and the frequency of spontaneous contractions are increased by  $\alpha_1$ -adrenoceptor stimulation and depressed by  $\beta$ -adrenoceptor stimulation. The predominant  $\alpha_1$ -adrenoceptor subtype has the pharmacological characteristics of the  $\alpha_{1A/L}$ -adrenoceptor subtype, while  $\beta_2$ -adrenoceptors (with possibly a  $\beta_1$ - contribution for tension) appear to be the predominant receptors mediating inhibitory responses.

## References


1. [Chess-Williams R. Muscarinic receptors of the urinary bladder: detrusor, urothelial and prejunctional. \*Auton Autacoid Pharmacol.\* 2002;22:133-145.](#)
2. [Michel MC, Vrydag W. Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. \*Br J Pharmacol.\* 2006;147 Suppl 2:S88-119.](#)
3. [Birder LA. Urothelial signaling. \*Auton Neurosci.\* 2010;153:33-40.](#)
4. [Moro C, Leeds C, Chess-Williams R. Contractile activity of the bladder urothelium/lamina propria and its regulation by nitric oxide. \*Eur J Pharmacol.\* 2012;674:445-449.](#)
5. [Sadananda P, Chess-Williams R, Burcher E. Contractile properties of the pig bladder mucosa in response to neurokinin A: a role for myofibroblasts? \*Br J Pharmacol.\* 2008;153:1465-1473.](#)
6. [Mattiasson A, Andersson KE, Sjogren C. Contractant and relaxant properties of the female rabbit urethral submucosa. \*J Urol.\* 1985;133:304-310.](#)
7. [Zygmunt PK, Persson K, Alm P, et al. The L-arginine/nitric oxide pathway in the rabbit urethral lamina propria. \*Acta Physiol Scand.\* 1993;148:431-439.](#)
8. [Moro C, Uchiyama J, Chess-Williams R. Urothelial/lamina propria spontaneous activity and the role of M3 muscarinic receptors in mediating rate responses to stretch and carbachol. \*Urology.\* 2011;78:1442 e1449-1415.](#)
9. [Dixon JS, Jen PY, Gosling JA. Tyrosine hydroxylase and vesicular acetylcholine transporter are coexpressed in a high proportion of intramural neurons of the human neonatal and child urinary bladder. \*Neurosci Lett.\* 1999;277:157-160.](#)

10. [Jen PY, Dixon JS, Gosling JA. Immunohistochemical localization of neuromarkers and neuropeptides in human fetal and neonatal urinary bladder. \*Br J Urol.\* 1995;75:230-235.](#)
11. [Alexander SPH, Mathie A, Peters JA. Guide to Receptors and Channels \(GRAC\), 5th edition. \*Br J Pharmacol.\* 2011;164 Suppl 1:1-2.](#)
12. Flavahan NA, Vanhoutte PM.  $\alpha$ 1-Adrenoceptor subclassification in vascular smooth muscle. *Trends in Pharmacol Sci.* 1986;7:347-349.
13. Otsuka A, Shinbo H, Matsumoto R, et al. Expression and functional role of beta-adrenoceptors in the human urinary bladder urothelium. *Naunyn Schmiedebergs Arch Pharmacol.* 2008;377:473-481.
14. [Crowe R, Burnstock G. A histochemical and immunohistochemical study of the autonomic innervation of the lower urinary tract of the female pig. Is the pig a good model for the human bladder and urethra? \*J Urol.\* 1989;141:414-422.](#)
15. [Goepel M, Wittmann A, Rubben H, et al. Comparison of adrenoceptor subtype expression in porcine and human bladder and prostate. \*Urol Res.\* 1997;25:199-206.](#)
16. [Sibley GN. A comparison of spontaneous and nerve-mediated activity in bladder muscle from man, pig and rabbit. \*J Physiol.\* 1984;354:431-443.](#)
17. Knepper SM, Buckner SA, Brune ME, et al. A-61603, a potent alpha 1-adrenergic receptor agonist, selective for the alpha 1A receptor subtype. *J Pharmacol Exp Ther.* 1995;274:97-103.
18. Noble AJ, Chess-Williams R, Couldwell C, et al. The effects of tamsulosin, a high affinity antagonist at functional alpha 1A- and alpha 1D-adrenoceptor subtypes. *Br J Pharmacol.* 1997;120:231-238.


19. [Conley RK, Williams TJ, Ford AP, et al. The role of alpha\(1\)-adrenoceptors and 5-HT\(1A\) receptors in the control of the micturition reflex in male anaesthetized rats. \*Br J Pharmacol.\* 2001;133:61-72.](#)
20. Williams TJ, Blue DR, Daniels DV, et al. In vitro alpha1-adrenoceptor pharmacology of Ro 70-0004 and RS-100329, novel alpha1A-adrenoceptor selective antagonists. *Br J Pharmacol.* 1999;127:252-258.
21. Piascik MT, Guarino RD, Smith MS, et al. The specific contribution of the novel alpha-1D adrenoceptor to the contraction of vascular smooth muscle. *J Pharmacol Exp Ther.* 1995;275:1583-1589.
22. [Yang HT, Endoh M. Pharmacological evidence for alpha\(1D\)-adrenoceptors in the rabbit ventricular myocardium: analysis with BMY 7378. \*Br J Pharmacol.\* 1997;122:1541-1550.](#)
23. Ford AP, Arredondo NF, Blue DR, Jr., et al. RS-17053 (N-[2-(2-cyclopropylmethoxyphenoxy)ethyl]-5-chloro-alpha, alpha-dimethyl-1H-indole-3-ethanamine hydrochloride), a selective alpha 1A-adrenoceptor antagonist, displays low affinity for functional alpha 1-adrenoceptors in human prostate: implications for adrenoceptor classification. *Mol Pharmacol.* 1996;49:209-215.
24. Ford AP, Daniels DV, Chang DJ, et al. Pharmacological pleiotropism of the human recombinant alpha1A-adrenoceptor: implications for alpha1-adrenoceptor classification. *Br J Pharmacol.* 1997;121:1127-1135.
25. Nishimune A, Suzuki F, Yoshiki H, et al. Alpha 1-adrenoceptor pharmacome: alpha 1L-adrenoceptor and alpha 1A-adrenoceptor in the lower urinary tract. *Int J Urol.* 2010;17:31-37.
26. [Fry CH, Sui GP, Kanai AJ, et al. The function of suburothelial myofibroblasts in the bladder. \*Neurourol Urodyn.\* 2007;26:914-919.](#)

27. Kanai A, Wyndaele JJ, Andersson KE, et al. Researching bladder afferents- determining the effects of beta(3) -adrenergic receptor agonists and botulinum toxin type-A. *Neurourol Urodyn*. 2011;30:684-691.
28. Kanai A, Roppolo J, Ikeda Y, et al. Origin of spontaneous activity in neonatal and adult rat bladders and its enhancement by stretch and muscarinic agonists. *Am J Physiol Renal Physiol*. 2007;292:F1065-F1072.
29. [Ikeda Y, Birder L, Buffington C, et al. Mucosal muscarinic receptors enhance bladder activity in cats with feline interstitial cystitis. \*J Urol\*. 2009;181:1415-1422.](#)


## Figure legends



**Fig. 1.** Typical experimental traces showing the effects of adrenoceptor agonists on urothelium and lamina propria contractile activity. [A] Noradrenaline (10 $\mu$ M) in the presence of phentolamine (10 $\mu$ M), [B] noradrenaline (10 $\mu$ M) in the presence of propranolol (1 $\mu$ M), [C] isoprenaline (1 $\mu$ M), [D] phenylephrine (100 $\mu$ M), [E] salbutamol (1 $\mu$ M) and [F] A61603 (10 $\mu$ M).



**Fig. 2. Upper figure:** Frequency and tension responses of urothelium/lamina propria strips induced by phenylephrine (100 $\mu$ M), in the absence (shaded columns) and in the presence (open columns) of antagonists: RS100329 (10nM, n=8), tamsulosin (3nM, n=8), BMY7378 (100nM, n=8), prazosin (10nM, n=10) and RS17053 (1 $\mu$ M, n=8). **Lower Figure:** Frequency and tension inhibitions induced by isoprenaline in the absence (shaded columns) and presence (open columns) of antagonists: propranolol (100nM, n=8), CGP20712A (30nM, n=8), ICI118551 (70nM, n=8), SR59230A (30nM, n=8), and a combination of ICI118551 (70nM) & CGP20721A (30nM, n=11, CGP & ICI). Responses are expressed as the percentage increase (upper figure) or inhibition (lower figure) of rate and tension. Columns represent the mean  $\pm$  SEM. Student's two-tailed *t*-test: \**P* < 0.05, \*\**P* < 0.01, \*\*\**P* < 0.001.



**Fig. 3.** Relative expression of each adrenoceptor gene. Expression values are based relative to  $\beta$ -actin expression for the  $\alpha$ -adrenoceptors (upper panel) and  $\beta$ -adrenoceptors (middle panel) and expressed as the mean  $\pm$  SEM (n=8 for each). Lower panel: Porcine receptor-specific PCR primer sequence and PCR amplicon sizes.

**Table 1.** Frequency and tension responses of urothelium/lamina propria to noradrenaline.

<b>Drug</b>	<b>Change in frequency (cycles min<sup>-1</sup>)</b>	<b>Change in tension (g)</b>	<b>n</b>
Noradrenaline (10 µM)	-0.57 ± 0.24	-0.64 ± 0.16	8
Noradrenaline (10 µM) + Phentolamine (10 µM)	-1.40 ± 0.25 <sup>a</sup>	-0.82 ± 0.06	8
Noradrenaline (10 µM) + Propanolol (1 µM)	1.34 ± 0.20 <sup>b</sup>	0.76 ± 0.13 <sup>b</sup>	8

Values are mean ± SEM.

<sup>a</sup>Significantly different from noradrenaline alone, P < 0.05 (ANOVA)

<sup>b</sup>Significantly different from noradrenaline alone, P < 0.01 (ANOVA)